AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1103, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France. Source
No articles found.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Bellicum Pharmaceuticals is a clinical-stage bi...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company fo...
Portola Pharmaceuticals is a global, commercial...
Join the National Investor Network and get the latest information with your interests in mind.